http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2697976-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7d1e513038cfe84ac871f7e6aa323926 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-369 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-0476 |
| filingDate | 2019-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_37a28c01b9d632ba2d30d450fdbbc03d |
| publicationDate | 2019-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2697976-C1 |
| titleOfInvention | Method of selecting a therapeutic approach to mental disorder |
| abstract | FIELD: medicine; psychophysiology.SUBSTANCE: invention refers to medicine, psychiatry, psychology and can be used to select a therapeutic approach to mental disorder. Performing the immunological, pathopsychological and neurophysiological studies. Immunological examination involves the following: activity of leukocyte elastase (LE), the level of autoantibodies to neuroscientific proteins S-100 (aAT-S100), the level of autoantibodies to myelin basic protein (aAT-MBP), concentration of C-reactive protein (CRP) in blood serum. Pathopsychological examination is used to determine the state of functioning of mental spheres. Neurophysiological examination is carried out by performing EEG and evaluating parameters of evoked potentials by tests: antisaccades, P50, startle reflex (SR). Type of mental disorder is determined based on the set of obtained data. Presence of schizophrenia is established in case of detecting: level LE more than 259 nmol/min ml, level aAT-S 100 and/or aAT-MBP more than 0.81 units o.d., CRP more than 5 mg/l; presence of disturbed thinking in the form of at least one of the following: disorganization, inconsistency, versatility, paralogicality, disintegration, slipping, distortion of generalization processes; presence of emotional disorders: inadequacy of emotions and/or ambivalence; deviation in all three tests or two tests: antisaccades and P50. Presence of a schizotypical disorder is established in case of detecting: a level LE higher than 259 nmol/min ml, aAT-S 100 level below 0.9 units o.d., level aAT-MBP more than 0.81 units o.d., CRP not more than 5 mg/l; presence of thinking disorders by type of overvalued ideas, obsessions in the absence of delusions, disconnection and disorganization of thinking; presence of emotional disorders in the form of at least one of the following: anxiety, fear, depression, social self-isolation; deviation in antisaccade test or in two tests: antisaccades and SR. Presence of non-psychotic disorders – affective, neurotic or personality disorders, is established in case of detecting: a level LE below 280 nmol/min ml, aAT S100 and OBM levels below 0.81 units o.d., CRP up to 5 mg/l; absence of thinking disorders in the form of: disorganization, inconsistency, versatility, paralogicality, breaking, slipping, distortion of generalization processes; presence of emotional disorders in the form of at least one of the following: anxiety, fear, depression, social self-isolation; absence of deviations in three neurophysiological tests or presence of isolated deviation in SR test. If observing schizophrenia, each session of the psychotherapeutic treatment involves: during the acute process: rational psychotherapy with establishing a confidential contact and setting the need for treatment; after relief of acute process: rational psychotherapy with establishment of need for treatment; neurolinguistic programming aimed at replacing negative experiences with positive, psychoemotional state BFB-therapy involving biofeedback and neurofeedback; when achieving stabilization of the condition: rational psychotherapy, during which forming an image of a positive future and motivated to achieve the desired result, neurolinguistic programming aimed at replacing negative experiences with positive, psychoemotional state BFU-therapy involving biofeedback and neurofeedback, Erickson's hypnosis, in the process of which psychopathological symptoms are recovered; psychotherapeutic exposure is combined with receiving psychopharmacological treatment, including neuroleptics and antidepressants selected based on leading psychopathological syndrome. If observing a schizotypical disorder, each psychotherapeutic exposure involves: during the acute process: rational psychotherapy with establishing a confidential contact and setting the need for treatment, as well as Erickson's hypnosis, in the process of which the psychopathological symptoms are recovered; after acute relief of the process and when the condition stabilizes: rational psychotherapy, during which the patient is explained to the psychopathological mechanisms of his painful symptoms and inadequate behavioral reactions, forming an image of a positive future and motivating to achieve the desired result; neurolinguistic programming aimed at replacing negative experiences with positive ones; psychoemotional state BFU-therapy involving biofeedback and neurofeedback; Erickson's hypnosis, in the process of which psychopathological symptoms are recovered; psychotherapeutic exposure is performed with underlying psychopharmacological treatment, including neuroleptics, antidepressants and tranquillizers selected taking into account leading psychopathological syndrome. If observing a non-psychotic disorder, each session of the psychotherapeutic exposure involves: during the acute process: rational psychotherapy with establishing a confidential contact and setting the need for treatment, as well as Erickson's hypnosis, in the process of which psycho |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2736803-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2736711-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2736707-C1 |
| priorityDate | 2019-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 96.